229 related articles for article (PubMed ID: 17060857)
1. Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients.
Naesens M; Kuypers DR; Verbeke K; Vanrenterghem Y
Transplantation; 2006 Oct; 82(8):1074-84. PubMed ID: 17060857
[TBL] [Abstract][Full Text] [Related]
2. C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation.
Baldelli S; Merlini S; Perico N; Nicastri A; Cortinovis M; Gotti E; Remuzzi G; Cattaneo D
Pharmacogenomics; 2007 Sep; 8(9):1127-41. PubMed ID: 17924828
[TBL] [Abstract][Full Text] [Related]
3. Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients.
Miura M; Satoh S; Inoue K; Kagaya H; Saito M; Inoue T; Suzuki T; Habuchi T
Eur J Clin Pharmacol; 2007 Dec; 63(12):1161-9. PubMed ID: 17906856
[TBL] [Abstract][Full Text] [Related]
4. UGT1A9, UGT2B7, and MRP2 genotypes can predict mycophenolic acid pharmacokinetic variability in pediatric kidney transplant recipients.
Fukuda T; Goebel J; Cox S; Maseck D; Zhang K; Sherbotie JR; Ellis EN; James LP; Ward RM; Vinks AA
Ther Drug Monit; 2012 Dec; 34(6):671-9. PubMed ID: 23131697
[TBL] [Abstract][Full Text] [Related]
5. The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients.
Kuypers DR; Naesens M; Vermeire S; Vanrenterghem Y
Clin Pharmacol Ther; 2005 Oct; 78(4):351-61. PubMed ID: 16198654
[TBL] [Abstract][Full Text] [Related]
6. Rifampin induces alterations in mycophenolic acid glucuronidation and elimination: implications for drug exposure in renal allograft recipients.
Naesens M; Kuypers DR; Streit F; Armstrong VW; Oellerich M; Verbeke K; Vanrenterghem Y
Clin Pharmacol Ther; 2006 Nov; 80(5):509-21. PubMed ID: 17112807
[TBL] [Abstract][Full Text] [Related]
7. Influence of uridine diphosphate (UDP)-glucuronosyltransferases and ABCC2 genetic polymorphisms on the pharmacokinetics of mycophenolic acid and its metabolites in Chinese renal transplant recipients.
Zhang WX; Chen B; Jin Z; Yu Z; Wang X; Chen H; Mao A; Cai W
Xenobiotica; 2008 Nov; 38(11):1422-36. PubMed ID: 18946804
[TBL] [Abstract][Full Text] [Related]
8. Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients.
Miura M; Kagaya H; Satoh S; Inoue K; Saito M; Habuchi T; Suzuki T
Ther Drug Monit; 2008 Oct; 30(5):559-64. PubMed ID: 18695635
[TBL] [Abstract][Full Text] [Related]
9. Steady-state pharmacokinetics of mycophenolic acid in renal transplant patients: exploratory analysis of the effects of cyclosporine, recipients' and donors' ABCC2 gene variants, and their interactions.
Božina N; Lalić Z; Nađ-Škegro S; Borić-Bilušić A; Božina T; Kaštelan Ž; Trkulja V
Eur J Clin Pharmacol; 2017 Sep; 73(9):1129-1140. PubMed ID: 28624888
[TBL] [Abstract][Full Text] [Related]
10. Influence of MRP2 on MPA pharmacokinetics in renal transplant recipients-results of the Pharmacogenomic Substudy within the Symphony Study.
Lloberas N; Torras J; Cruzado JM; Andreu F; Oppenheimer F; Sánchez-Plumed J; Gentil MÁ; Brunet M; Ekberg H; Grinyó JM;
Nephrol Dial Transplant; 2011 Nov; 26(11):3784-93. PubMed ID: 21427078
[TBL] [Abstract][Full Text] [Related]
11. Current target ranges of mycophenolic acid exposure and drug-related adverse events: a 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients.
Kuypers DR; de Jonge H; Naesens M; de Loor H; Halewijck E; Dekens M; Vanrenterghem Y
Clin Ther; 2008 Apr; 30(4):673-83. PubMed ID: 18498916
[TBL] [Abstract][Full Text] [Related]
12. The impact of renal allograft function on exposure and elimination of mycophenolic acid (MPA) and its metabolite MPA 7-O-glucuronide.
Naesens M; de Loor H; Vanrenterghem Y; Kuypers DR
Transplantation; 2007 Aug; 84(3):362-73. PubMed ID: 17700162
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic modeling of enterohepatic circulation of mycophenolic acid in renal transplant recipients.
Colom H; Lloberas N; Andreu F; Caldés A; Torras J; Oppenheimer F; Sanchez-Plumed J; Gentil MA; Kuypers DR; Brunet M; Ekberg H; Grinyó JM
Kidney Int; 2014 Jun; 85(6):1434-43. PubMed ID: 24402086
[TBL] [Abstract][Full Text] [Related]
14. Renal glucuronidation and multidrug resistance protein 2-/ multidrug resistance protein 4-mediated efflux of mycophenolic acid: interaction with cyclosporine and tacrolimus.
El-Sheikh AA; Koenderink JB; Wouterse AC; van den Broek PH; Verweij VG; Masereeuw R; Russel FG
Transl Res; 2014 Jul; 164(1):46-56. PubMed ID: 24486136
[TBL] [Abstract][Full Text] [Related]
15. UGT1A9 -275T>A/-2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients.
van Schaik RH; van Agteren M; de Fijter JW; Hartmann A; Schmidt J; Budde K; Kuypers D; Le Meur Y; van der Werf M; Mamelok R; van Gelder T
Clin Pharmacol Ther; 2009 Sep; 86(3):319-27. PubMed ID: 19494809
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetic impact of UDP-glucuronosyltransferase metabolic pathway and multidrug resistance-associated protein 2 transport pathway on mycophenolic acid in thoracic transplant recipients: an exploratory study.
Ting LS; Benoit-Biancamano MO; Bernard O; Riggs KW; Guillemette C; Ensom MH
Pharmacotherapy; 2010 Nov; 30(11):1097-108. PubMed ID: 20973683
[TBL] [Abstract][Full Text] [Related]
17. The association of the UGT1A8, SLCO1B3 and ABCC2/ABCG2 genetic polymorphisms with the pharmacokinetics of mycophenolic acid and its phenolic glucuronide metabolite in Chinese individuals.
Geng F; Jiao Z; Dao YJ; Qiu XY; Ding JJ; Shi XJ; Li ZD; Zhong MK
Clin Chim Acta; 2012 Apr; 413(7-8):683-90. PubMed ID: 22227166
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of mycophenolate mofetil and its glucuronide metabolites in healthy volunteers.
Lévesque E; Benoit-Biancamano MO; Delage R; Couture F; Guillemette C
Pharmacogenomics; 2008 Jul; 9(7):869-79. PubMed ID: 18597651
[TBL] [Abstract][Full Text] [Related]
19. Genetic polymorphisms of MRP2 and UGT2B7 and gastrointestinal symptoms in renal transplant recipients taking mycophenolic acid.
Yang JW; Lee PH; Hutchinson IV; Pravica V; Shah T; Min DI
Ther Drug Monit; 2009 Oct; 31(5):542-8. PubMed ID: 19730281
[TBL] [Abstract][Full Text] [Related]
20. AcylMPAG plasma concentrations and mycophenolic acid-related side effects in patients undergoing renal transplantation are not related to the UGT2B7-840G>A gene polymorphism.
van Agteren M; Armstrong VW; van Schaik RH; de Fijter H; Hartmann A; Zeier M; Budde K; Kuypers D; Pisarski P; Le Meur Y; van der Werf M; Mamelok RD; Oellerich M; van Gelder T
Ther Drug Monit; 2008 Aug; 30(4):439-44. PubMed ID: 18641546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
